The epidermal growth factor receptor, EGFR, is a cellular transmembrane receptor expressed in a number of different tumor types including prostate and non-small cell lung cancer (NSCLC)¹,². The prevalence of EGFR mutations in NSCLC is 10-15% in Western and up to 50% in Asian patients². The most common EGFR mutations are the L858R mutation in exon 21 and deletions in exon 19².
The Idylla™ EGFR Mutation Assay allows detection of EGFR mutations directly from formalin-fixed paraffin-embedded (FFPE) tissue sections in approx. 150 minutes with less than 2 minutes hands-on time.
The Idylla™ EGFR Mutation Assay, performed on the Biocartis Idylla™ system, is a sample-to-result real-time PCR assay available for the qualitative detection of 51 mutations in exons 18, 19, 20 and 21 of the EGFR gene. The Idylla™ EGFR Mutation Assay efficiently liberates DNA directly from FFPE tissue and performs multiplex real-time PCR amplification and detection. Fully automated software interpretation and reporting is also integrated, and provides a result in approx. 150 minutes.
YOU ARE ABOUT TO EXIT FOR ANOTHER BIOCARTIS COUNTRY OR REGION SPECIFIC WEBSITE
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
DO YOU WISH TO CONTINUE AND EXIT THIS SITE?
DISCLAIMER:
This information concerns a use that has not been approved or cleared by the Food and Drug Administration.
Biocartis is recruiting centers for a prospective biomarker study comparing turnaround times of standard of care methods and biomarker testing with Idylla™.
DISCLAIMER:
This presentation is intellectual property of the individual presenters. The opinions and conclusions expressed in these presentations are those of the individual presenters and do not necessarily reflect the views and opinions of Biocartis and/or its employees.
One of the biggest challenges oncology labs face with biomarker testing is the ability to obtain samples of sufficient size and quality. With the Idylla™ system only a minimal amount of sample is needed. For solid biopsies, just one slice of tissue is enough and our plasma-based assays require only 1 ml of plasma.
